162 related articles for article (PubMed ID: 6743563)
1. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis.
Burstein SA; Malpass TW; Yee E; Kadin M; Brigden M; Adamson JW; Harker LA
Br J Haematol; 1984 Jul; 57(3):383-92. PubMed ID: 6743563
[TBL] [Abstract][Full Text] [Related]
2. Platelet alpha-granule release in chronic myeloproliferative disorders with thrombocytosis.
Sacchi S; Curci G; Piccinini L; Messerotti A; Cucci F; Bursi R; Zaniol P; Torelli U
Scand J Clin Lab Invest; 1986 Apr; 46(2):163-6. PubMed ID: 2424075
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Gersuk GM; Carmel R; Pattengale PK
Blood; 1989 Nov; 74(7):2330-4. PubMed ID: 2804368
[TBL] [Abstract][Full Text] [Related]
4. Megakaryocytes and myelofibrosis in gray platelet syndrome.
Caen JP; Deschamps JF; Bodevin E; Bryckaert MC; Dupuy E; Wasteson A
Nouv Rev Fr Hematol (1978); 1987; 29(2):109-14. PubMed ID: 3615193
[TBL] [Abstract][Full Text] [Related]
5. Raised urinary calmodulin levels in idiopathic myelofibrosis: possible implications for the aetiology of fibrosis.
Eastham JM; Reilly JT; Mac Neil S
Br J Haematol; 1994 Mar; 86(3):668-70. PubMed ID: 8043453
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Wehmeier A; Fricke S; Scharf RE; Schneider W
Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
[TBL] [Abstract][Full Text] [Related]
7. Abnormal levels of platelet-specific proteins and mitogenic activity in myeloproliferative disease.
Rueda F; Piñol G; Marti F; Pujol-Moix N
Acta Haematol; 1991; 85(1):12-5. PubMed ID: 1826402
[TBL] [Abstract][Full Text] [Related]
8. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
Martyré MC; Magdelenat H; Bryckaert MC; Laine-Bidron C; Calvo F
Br J Haematol; 1991 Jan; 77(1):80-6. PubMed ID: 1998600
[TBL] [Abstract][Full Text] [Related]
9. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders.
Katoh O; Kimura A; Kuramoto A
Am J Hematol; 1988 Apr; 27(4):276-80. PubMed ID: 3354562
[TBL] [Abstract][Full Text] [Related]
11. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders.
Malpass TW; Savage B; Hanson SR; Slichter SJ; Harker LA
J Lab Clin Med; 1984 Jun; 103(6):894-904. PubMed ID: 6233383
[TBL] [Abstract][Full Text] [Related]
12. [Beta-thromboglobulin and platelet factor 4 in a follow-up of acute myelofibrosis (megakaryoblastic leukemia)].
Palomera Bernal L; García Díez I
Med Clin (Barc); 1990 Jun; 95(1):21-4. PubMed ID: 2146451
[TBL] [Abstract][Full Text] [Related]
13. Detection of enhanced in vivo platelet alpha-granule release in different patient groups--comparison of beta-thromboglobulin, platelet factor 4 and thrombospondin assays.
Lane DA; Ireland H; Wolff S; Ranasinghe E; Dawes J
Thromb Haemost; 1984 Oct; 52(2):183-7. PubMed ID: 6084323
[TBL] [Abstract][Full Text] [Related]
14. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
15. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
Brodsky I; Kahn SB; Ross EM; Petkov G
Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
[No Abstract] [Full Text] [Related]
16. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
Murphy S; Davis JL; Walsh PN; Gardner FH
Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
[TBL] [Abstract][Full Text] [Related]
17. Platelet defects in the myeloproliferative disorders.
Inceman S; Tangün Y
Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
[No Abstract] [Full Text] [Related]
18. Platelet and plasma beta thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis.
Boughton BJ; Allington MJ; King A
Br J Haematol; 1978 Sep; 40(1):125-32. PubMed ID: 81681
[TBL] [Abstract][Full Text] [Related]
19. Platelet phospholipids in thrombocytosis due to myeloproliferative disorders.
Breuer JH; Harsányi V; Solti V; Hollán SR
Haemostasis; 1981; 10(3):134-40. PubMed ID: 7262643
[TBL] [Abstract][Full Text] [Related]
20. Urinary hydroxyproline excretion in the myelofibrosis-osteomyelosclerosis syndrome and related diseases.
Hasselbalch H
Eur J Haematol; 1987 Nov; 39(5):447-51. PubMed ID: 3691762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
